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Summary
Attitudes to obesity are changing. It is currently
regarded as a common, multifactorial disorder with
serious medical and psychological consequences. It
is also resistant to treatment. Recent research with
experimental animals has given new insights into the
molecular pathology of this condition and gives some
hope of novel therapeutic intervention.
SAtr AIed J 1986; 69: 185-190.
Obesity is a symptom frequently described l,2 as the presence
of more than 20 - 30% of body weight as fat (mainly triglyce-
rides). It should not be confused with overweight (composed
of organ, bone, muscle and fat mass), oedema or mild farness.
The prevalence of obesity in Western society is increasing.3 It
is frequently associated with an increased risk for renal disease,
cirrhosis of the liver, heart disease (i.e. sudden death, angina
pectoris, congestive heart failure but not coronary thrombosis),
gallbladder and endocrine disease, osteo-arthritis, hypertension,
diabetes mellitus, gout, suboptimal pulmonary function and
impaired life expectancy.I,4 Mortality is not a linear function
of body weight, but increases dramatically above a certain
figure. 5,6
Obesity is frequently associated with increased blood levels
of free fatty acids, triglycerides, uric acid, glucose and insulin,
and with decreased levels and response of growth hormone
(increased synthesis of cholesterol has also been reported,
although blood levels may be normal). (These parameters are
of course influenced by diet and whether the person is in a
dynamic or static phase of weight gain.2) The socio-economic
cost to society is considerable, and it must be emphasized that
obesity as defmed is a public health problem and not one
merely cosmetic in nature. To the individual the cosmetic
aspect may, however, represent a severe social and psycholorcal
handicap which can dramatically alter his quality oflifeY,
The aetiology of this condition is multifactorial and may
involve hypothalamic, neural and neurotransminer mechanisms
and/or fenetic, hormonal, metabolic and/or nutritional
factors. I, ,10 The primary derangement is an increased caloric
intake (metabolizable energy) in relation to caloric expenditure.
This may not imply hyperphagia, but may be related to
increased caloric density due to eating panern or diet, I reduced
caloric expenditure due to physical or mental inertia, II increased
fat anabolism due to differential tissue utilization of glucose, 11,12
or to a more efficient catabolism,13 i.e. reduced thermogenic
capacity.
Obesity therefore represents a syndrome rather than a specific
disease. It is not a self-inflicted condition any more than is
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heart disease or depression, but represents a di turbance in
whole-body energy metabolism which may have various aetio-
logical factors. 1,10
The syndromes of obesity are: (I) genetic (e.g. Prader-Willi
syndrome); (il) nutritional (diet, eating panern); (iil) hypo-
thalamic (e.g. tumour); (iv) endocrine (e.g. Cu hing's syndrome,
adult-onset diabetes mellitus); (v) metabolic (distribution and
activation of enzymes in various tissues); (VI) hormonal (distri-
bution of receptors in various tissues); and (viI) psychological
(reactive obesity). (Genetic and endocrine factors are not dealt
with in this review. For excellent recent summaries see Bray
and York lo and Brayl4 (autonomic and adrenal hypothesis)
respectively. Genetically selected animal models have contri-
buted enormously to the study of obesity.)
These syndromes are not mutually exclusive; several of
them may interact to produce the resultant obesity.
Nutritional status and physical exercise are the primary
contributing factors to obesity which are recognized by the
man in the street (i.e. glunony and sloth) and indeed by many
medical practitioners.6 Although these factors are present in
the majority of cases of obesity encountered, they are possibly
overlaid on (for example) a hypothalarnic-mediated hyperphagia
or on a genetic predisposition which results in an altered
metabolic profile and in a person more susceptible to obesity.
Established obesity may be maintained in the presence of a
'normal' nutritional intake,ls and in experimental animals
obesity can develop in the absence of hyperphagia. 16
Areas of the hypothalamus are thought to control hunger
(ventrolateral area (VLH))17,18 and satiety (ventromedial area
(VMH)).19 The noradrenergic neurons passing through the
VMH area (ventromedial bundle) may be involved in these
neuro-endocrine control mechanisms (VMH = a-adreno-
ceptors; VLH = ,B-adrenoceptors) and they may interact with
the nigrostriatal dopaminergic (VLH) and serotonergic (VMH)
neurons. 20 Certain anorexiant drugs have been shown to interact
with these neurons, e.g. amphetamines (dopamine, noradrena-
line) and fenfluramine (dopamine, serotonin).20 Gastric disten-
sion acting through neural pathways (vagus nerve) represents a
crude physiological signal of satiety, although there may be
feedback from the gut to the hypothalamus through certain
gut hormones, e.g. bombesin, cholecystokinin.20 Other meta-
bolic products have also been proposed to be involved in
metabolic feedback on hypothalamic control of appetite, e.g.
short-chain fany acids,21 tryptophan. 22 It has also been
suggested20 that glucose or insulin may act on the VMH area
(satiety) and increase noradrenergic output while free fany
acids may act on the VLH area (hunger). Opioid receptors in
the reward areas of the brain may also be involved in appetite
controL21
Classification
The obesities have been classified morphologically into rwo
typeS:23 (I) hypertrophic (± 80%) - increased size of fat cells (also
known as alimentary, social, exogenous, mobile, acquired or late-
onset); and (il) hyperplastic (± 20%) - increased number of fat
cells (also known as endogenous, essential, metabolic, hypercellular,
pathological, refractory or early-onset).
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Hyperuophic obesity is generally of maturity-onset (> 30 years
of age) and mild. It responds to diet and exercise and is frequently
found in lower socio-economic groups. It should be noted that the
division into the two types is not clear-cut and not universally
accepted. An increase in adipose cell size is present in all forms of
obesity, and the overall incidence of obesity increases with age (up
to ± 50 years).
Hyperplastic obesity has generally an early age of onset and is
more refractoty to treatment. The increase in adipocyte cell
number is generally not reversible (although this can be achieved
transiently by surgical lipectomy and may occur with 'prolonged'
weight loss) even in the face of weight loss, which represents a
reduction in fat cell size but not in number.24 This adipocyte
hyperplasia represents a significant factor in obesity refractory to
long-term treatment. Adipocyte proliferation mainly takes place
early in life « 2 years) and at puberty (females), but when
adipocytes reach a certain size, adipocyte proliferation occurs at
any age/4 - 26 and thereafter adipocyte number correlates with the
extent of obesity I Therefore while fat infants frequently become
fat adults, this is not always the case, although neonatal or infant
adipocyte hyperplasia represents an increased risk factor for future
adult obesity. Conversely, hyperplastic obesity has on occasions
been shown to be adult-onset in nature, i.e. reactive obesity.
It is a maner of common experience that each adult has the
capacity to maintain a fairly constant body weight over prolonged
periods. This requires physiological regulation of some
precision21.28 Certain perturbations may alter this weight (dynamic
phase) and possibly establish a new steady state (static phase). In
respect of the development of obesity, the new steady state may be
one where adipocyte hyperplasia during the dynamic phase has led
to an increase in weight. This new steady state can be maintained
without increased nutritional intake and becomes the new norm
for that individual. 24,26.27 (Certain people, however, continually put
on weight, particularly if obesity is already well-established.)
Various factors have been suggested to account for the body's
ability to maintain relatively constant weight. 29 These have given
rise to the terms lipostat (long-term control),26,30 thermostat31 and
glucostat J2 (short-term control) and aminostatH (age-related
control). They represent anempts to explain weight homeostasis
on the basis of biochemical feedback of dietary metabolites on
hypothalamic regulation of appetite and metabolism (possibly all
these mechanisms operate and this makes weight control on the
basis of dietary content difficult as each dietary component may
trigger its own satiety signal). It has also been suggested that
insulin is involved in the short- (VMH area) and long-term (other
brain areas) control of weight homeostasis, and in stimulation of
sympathetic noradrenaline release. 34 None of these hypotheses has
been validated, but what is apparent is that during the dynamic
phase of obesity the body weight homeostatic mechanisms fail to
operate or are overridden.
In practical terms it means that established obesity (static
phase) is more refractoty to treatment, and that prolonged weight
loss is difficult to maintain.24 This may also be amibuted, in part,
to the difference in insulin response in adipocytes of varying size
(small> large) and to a reduction in thermogenesis on hypocaloric
intake.2
A further complication is the possibility that the nature of
adipocytes (omental or subcutaneous) may not be uniform. I This
may explain the characteristic distribution of fat found in certain
endocrine obesities.
Treatment
Obesity (particularly hyperplastic) represents an extremely
demanding therapeutic challenge.6 Most physicians, while not
completely in agreement with many widely publicized diets,
recommend caloric restriction on a balanced or supplemented diet,
mild aerobic exercise, and behavioural therapy for mild obesity.2.J5
Specific dietary restriction (i.e. popular diets) can increase indivi-
dual motivation and give an easy method for individual determina-
tion and control of caloric intake, and the reduction in food variety
reduces palatability and appetite but can lead to dietary deficiency
states. The importance of mild exercise should also be stressed.
The increased prevalence of obesity in handicapped children
suggests that lack of exercise may not only be a symptom charac-
teristic of obesity, but also contribute to its development. While
exercise as a treatment of obesity may have linle impact on overall
energy expenditure (basal metabolism, i.e. maintenance of vital
cell functions, accounts for the major part (60 - 70%) of energy
utilization13), it may alter hormonal or metabolic factors and
relieve secondary changes of obesity, e.g. insulin resistance, or
cause prolonged (± 24 hours) post-exercise changes in metabolic
rate which may contribute to continuing weight loss.
Psychological or environmental factors may also play a role in
the development of obesity. While normal people tend to start
(hunger signal) and Stop (satiety signal) eating in response to
internal physiological stimuli, indications36 are that obese people
tend to respond more readily to external appetite stimuli, i.e.
smell, taste and presentation of food. Such factors may override
internal hunger and satiety signals.
These internal signals may be manipulated with anorexiant
drugs, and their use (when recommended) is as a supplement to
hypocaloric diets, but behavioural therapy is important in long-
term weight loss, particularly as repeated unsuccessful anempts at
weight loss can alter metabolic response with the increased likeli-
hood of the development of more severe obesity in the future,3;
i.e. 'rebound effect' or 'adaptive hyperlipogenesis'. Such episodes
are also disheartening for the individual. Behavioural therapy aims
to reinforce altered activity parterns and lifestyle (it is difficult to
contemplate eating only pineapples for the rest of your life!), to
change priorities and gratification signals, and to build a bener
self-image and develop self-confidence and a sense of personal
responsibility.35
Therapy with anorexiant drugs, thyroid hormones or biguanides
is controversial and should be carried out under close medical
supervision, or after firm diagnosis of (for example) hypo-
thyroidism. Surgical intervention by intestinal bypass, gastric
banding or jaw wiring is recommended only for grossly obese
patients and these procedures are normally carried out in specialist
clinics and preceded by procedures to reduce oedema, improve
respiratory function and establish metabolic homeostasis. While
intestinal bypass has a good record in terms of prolonged weight
loss, it has many serious long-term side-effects.5 Suction lipectomy
should be performed by an experienced plastic surgeon and it is
intended more as a cosmetic procedure than as a treatment of
gross obesity.38
At the present time it must be stated that the results obtained in
the treatment of obesity are disheartening for both therapist and
subject. Nevertheless, more recent experiments with animal models
have given rise to new insights into the molecular pathology of
obesity which may find application in humans, and gives some
hope for novel therapeutic intervention in the near future.
While the first half of this presentation dealt mainly with caloric
intake, the second part will deal mainly with caloric expenditure.
New horizons
Thermogenesis
The role of thermogenesis in body-weight homeostasis was first
suggested by Rubner39 and Neumann40 in 1902. Temperature
homeostasis in man is controlled by areas of the hypothalamus,
and production of thermal energy is linked to oxygen consumption
and to the efficiency of generation or utilization of adenosine
triphosphate (ATP). After a meal there is an increase in body
temperature due to the processes of digestion and absorption. This
has been called the specific dynamic action of food. It has often
been equated with dietary-induced thermogenesis (DIT), although
this laner effect is more prolonged and depends on the nature of
the food and the metabolic fate of the absorbed nutrient. 13 The
DIT of food will be treated here as heat generation distinct from
what is known as adaptive or regulatory thermogenesis (AT) (this
has also been suggested to be a component of DIT), although the
DIT and AT effects may interact. AT (also known as non-
shivering thermogenesis: NST) is a metabolic response to cold
stress which is distinct from shivering thermogenesis (ST), which
is a neuromuscular response to sudden cold exposure. AT (NST)
has fearures in common with the action of noradrenaline at
thermoneutrality.41 It has been shown that genetically obese mice
have a reduced capacity for NST and are more sensitive to
prolonged exposure to reduced temperature. 20 In the presence of
cold exposure or increased noradrenergic output at thermo-
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Fig. 1. Diagram of a futile cycle, The two enzymes involved in the
cycle are E2 and E3 which control the conversion of substrates 5,
and 53' If both E2 (insulin) and E3 (noradrenaline) enzymes are
activated, a rapid cycle will be established with consumption of
ATP and thermogenesis, The flux across the cycle (5, - 5.) will
under these circumstances be reduced.
Adipocyte receptors
Adipocyte homeostasis has often been discussed in terms of the
lipogenic effect of insulin and the lipolytic effect of noradrenaline/
adrenaline (adrenocorticotrophic hormone, thyrotrophin and
glucagon are also lipolytic), It is now known that there are four
different types of adrenoceptors in human white adipose tissue -
13,,132' a, and 0'2' (This topic has recently been reviewed in depth
by Kather57 and by Fain and Garciii.-Sainz58 and will be discussed
only briefly.) (Adrenaline originates mainly in the adrenal medulla,
and noradrenaline is released from sympathetic nerve endings. 58
The role of this 'sympatho-adrenal system' in obesity has recently
been reviewed by Landsberg and Young. 59)
The 13,-receptors (adrenaline = noradrenaline) are linked to the
adenylate cyclase system and to the stimulation of lipolysis, and
this effect is inhibited by insulin. The 132-receptors (adrenaline>
noradrenaline) may be linked to the methylation of certain phospho-
lipids, and possibly to eicosanoid biosynthesis, although this is not
conclusive.58 The ratio of 13, : 132 receptors may vary with adipocyte
cell maturity, but both types are present on mature adipocytesY
The O',-receptors (noradrenaline) are coupled to the phosphati-
dylinositol cycle57 and to alterations in intracellular levels of
eicosanoids and calcium. 60-62 They are the predominant catechola-
mine receptors found on hepatocytes and they regulate glycogen
metabolism, i.e. inhibit glycogen synthetase, but they have no
established role in adipocyte lipolysis 57 They are absent in
subcutaneous adipose tissue but are present in omental adipocytes.63
The 0'2-receptors (adrenaline) are also coupled to the adenylate
cyclase system. While 13,-stimulation increases cyclic adenosine
monophosphate (cAMP) levels and lipolysis, 0!2-stimulation lowers
intracellular cAMP and inhibits lipolysis. In man, 0!2-adipocyte
responsiveness has been shown57 to be increased in areas of
preferred fat deposition, e.g. hip and gluteal regions. The ratio of
13, : 0!2 receptors and their individual responsiveness may be
influenced by thyroid hormones, i.e. hypothyroidism decreases 13,-
receptor response, hyperthyroidism decreases 0!2-receptor
responseY Hypothyroid rats have also been shown to have
increased levels of cAMP phosphodiesterase, increased transport
of hexoses into adipocytes and decreased levels of serum growth
hormone. 58 The 0!2-receptor responsiveness is (paradoxically)
increased in fasting subjects.
While 132- and O!,-receptor stimulation may influence intra-
cellular eicosanoid levels, the eicosanoids also have their own
adipocyte cell surface receptors. At nanomolar concentrations (in
the presence of guanosine triphosphate) prostaglandin (PG) E2 is a
potent inhibitor of catecholamine-induced lipolysis,57 while PGD2,
PGI 1 and micromolar concentrations of PGE2 stimulate lipolysis.
Scaramuzzi et al. 64 and Cunis-Prior65 have proposed that PG
metabolism may play a role in obesity, and may offer an area for
therapeutic intervention.
Adipose tissue metabolism is obviously complex, and despite
apparent morphological homogeneity, at the molecular level white
r-eutrality there is an increase in metabolic rate and cardiac output
lhich is inversely related to animal body weight (i.e. mice> rats
..> man in thermogenic response).42 The site of AT (NST) in manis thou?:ht to be skeletal muscle, liver and brown adipose tissue
(BAT). 3,44 Although BAT constitutes only 2% of body weight in
pumans, 30% of the mcrease in total cardiac output is diverted to
this tissue (in rats) under the influence of noradrenaline, and more
than 60% of the excess oxygen consumed (increased metabolic
r'ate) is taken up by BAT.45 Cold acclimatization has been shown
to increase the number of BAT cells in areas of mice normally
issociated with white adipocytes,46 and Rothwell and Stock41 have
clemonstrated an increased thermogenic response to noradrenaline
in cafeteria-fed obese rats during the period of subsequent weight
lPsS (22 days). BAT is highly vascularized and innervated, and
stimulation by noradrenaline is via sympathetic nerves and BAT
p-receptors. It may also be regulated by the VMH area of the
prain. 20 It has been proposed that altered blood flow gives rise to
tissue-specific (BAT) metabolism and oxygen consumption. Blood
flow to the hean, diaphragm (respiratory muscles), skin and white
:jdipose tissue of mice is increased after administration of nor-
:jdrenaline.20
BAT thermoregulation is derived from 13-oxidation of fatty
lIcids by BAT mitochondria and the uncoupling of subsequent
respiratory chain ATP synthesis from electron transpon. 48 This
ClCCurS through a leak in membrane proton conductance which is
rnediated by a 32000 MW polypeptide (thermo?enin), acetyl CoA
clr fatty acids and guanosine diphosphate.48,4 The result is an
increase in oxygen consumption and increased heat dissipation
clue to thermal leak from a relatively inefficient synthesis of ATP.
1"he obese person would in this respect appear to be more efficient
than the lean individual. (Such processes are used by the BAT of
llibernating animals on revival in spring,50 and these animals have
frequently been used as experimental models, e.g. hamsters.) (A
review of thermogenesis in BAT and its implications in obesity
llas recently been published by Himms-HagenY)
In other respects also obese people use energy more efficiently
than lean people. The activity of the Na/K-ATPase ion pump is
reduced in certain tissues of the obese mouse52 and man. 53 This
pump maintains intracellular ion gradients necessary for secretory
processes, enzyme action and neurotransmission. It requires ATP
and may be influenced by thytoid hormones (increased) and
insulin (decreased),53 but its role in obesity is not yet firmly
established.
Newsholme54 and Newsholme er al. 55 have proposed a further
component of thermoregulation which they suggest will give
increased sensitivity in metabolic regulation, and may produce
heat as a side-effect of ATP consumption. The term 'futile cycles'
has been used to describe these metabolic pathways. The concept
applies to independent (non-equilibrium) forward and reverse
reactions where ATP is consumed and heat is generated in an
exothermic (reverse) reaction. (It is through such reactions that
heat is generated for the flight of the bee.) These cycles have two
components necessary for cycling activity and the relative rate of
each reaction (i.e. forward and reverse) controls the flux through
(jr across the cycle, and the rate of cycling. The rate of cycling
Controls the heat generated, e.g. simultaneous high levels of
insulin (forward reaction) and noradrenaline (reverse reaction)
(;ould give a low cycle flux, a high cycling rate and substantial heat
I)roduction (Fig. 1).
Newsholme56 has reported that the rates of the triacylglycerol/
fatty acid, glucose/glucose-6-phosphate, fructose-6-phosphate/
f'ructose bisphosphate and glycogen/glucose-l-phosphate cycles
lire increased in BAT and/or white adipose tissue by cold stress,
rlOradrenergic stimulation and/or feeding. He has suggested that a
I:educed capacity for cycling may contribute to the development of
()besity.
Finally, it should be stated that increased thermogenesis must
involve increased heat loss to maintain thermoneutrality. Heat loss
Inay be reduced in the obese and this may limit thermogenesis.2
<::onversely, it has also been suggested that thermogenesis itself
Inay act as a satiety signal.
The AT (NST) in BAT, activity of the Na/K-ATPase pump
;md futile energy cycles may all be activated by noradrenaline,
which also increases cardiac output to specific tissues and increases
lnetabolic rate. Noradrenaline has specific adrenoceptors on both
white adipose tissue and BAT.
E,
5,----=--------'~~ 5,
ATP
~E2
phosphorylation
~ E. 5.
53 ---------'~~
J
dephosphorylation
Pi + energy
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adipocytes are heterogeneous. To complicate the picture further,
insulin (in the absence of calcium) has been shown to increase
intracellular levels of the breakdown products of the phosphati-
dylinositol cycle,66 and non-hormonal factors can affect catechola-
mine actions on lipolysis, e.g. cholera and pertussis toxin,
forskolin. 58
The four types of adrenoceptors are probably present in BAT,
although the presence of 0'2-receptors is not conclusive. Stimulation
of hamster BAT 0' I-receptors stimulates respiration, and the {3,-
receptors on BAT of rats stimulate lipolysis, respiration, cAMP
formation and thermogenesis and may be influenced by thyroid
hormones. 58
Insulin and the respiratory control of
metabolic fate
The preceding sections suggested that a more efficient catabolism
(i.e. defect in thermogenesis) or change in the catecholamine/
eicosanoid control of lipolysis may be present in obesity. A further
possibility is that there is a more efficient or increased fat anabolism
(i.e. lipogenesis). That is a shift in tissue (muscle - adipocyte)"·67,68
and metabolic priorities. Hyperinsulinaemia and peripheral insulin
resistance are often found in obesity. This resistance is not easy to
define (generally as decreased clearance of glucose from the circula-
tion), and it may apply to specific tissues. Whole-body measure-
ments of metabolic rate or reduced clearance of glucose from
plasma are difficult to interpret in this respect, and the ultimate
metabolic fate of glucose used as a measure of post-insulin-
receptor metabolism will influence conclusions drawn. Insulin has
been shown to increase glucose utilization for esterification of fatty
acids in large adipocytes. 69
It has been demonstrated in the fetus that hyperinsulinism gives
rise to hypoxia,"o-73 and it has been suggested that this hypoxia
may modify glucose metabolism and increase glycerol-3-phosphate
synthesis in white adipose tissue by shunting glucose through the
hexose monophosphate shunt pathway. 12 (This may be an anempt
to clear circulating glucose in a manner conservative with respect
to oxygen consumption. The contribution of the hexose mono-
phosphate shunt pathway to glucose metabolism in isolated rat
adipocytes has been shown to be increased by insulin and decreased
by noradrenaline?4 and growth hormone.?5) Increased export of
very-Iow-density lipoprotein (VLDL) from the liver has been
observed in obese rats76 and increased transport of this VLDL to
adipocytes would result in increased levels of adipocyte fatty acids,
and in the presence of increased glycerol-3-phosphate, increased
triglycerides, i.e. adipocyte hypertrophy. Insulin has been shown
to increase adipocyte lipoprotein lipase activity,77 and lipoprotein
lipase activity77 and fasting insulin levels78 have been correlated
with fat cell size. Respiratory embarrassment is also present in
gross obesity, and it has been suggested that this may be related
(exponentially) to the degree of obesity.?9
Thermogenesis (BAT, NAlK-ATPase and futile cycles) also
requires oxygen. Therefore oxygen utilization and the ultimate
tissue and metabolic fate of glucose may depend upon the availabi-
lity of oxygen and on the ratio of insulin: catecholamines, although
many other factors may act as fine controls, e.g. thyroid hormones.
Oxygen itself may exert a respiratory control on the action of
hormones,8o and it is interesting to speculate on the effect of
oxygenation on eicosanoid metabolism in the microcirculation,81 as
these compounds have potent vasoactive properties and are an
important part of the cell second messenger system. 60- 62 Hypoxia
is frequently found in grossly obese patients (e.g. pickwickian
syndrome), and a mechanism along the lines suggested may
contribute to a vicious cycle of hyperinsulinism, respiratory com-
promise, reduced thermogenesis, increased triglyceride synthesis,
continuing weight increase and obesity refractory to treatment.
Treatment
Experiments are continuing with centrally acting (noradrenergic
neurons), non-amphetamine appetite suppressants, e.g. mazindol
(Teronac; Wander), and sustained weight loss (± 12 months) on a
hypocaloric diet has been demonstrated.82 In man fenfluramine,
besides its effects on the central ne~vous system, has been shown
to increase uptake of glucose into muscle' in preference to adipose
tissue (an action which mimics the effect of mild exercise).83
Anempts have been made at dietary manipulation of thermo-
genesis (high-carbohydrate/low-protein diet)84 or eicosanoid levels
(evening primrose oil),85 but without obvious therapeutic potential
at this stage.
The complexity of adrenoreceptors in adipose tissue and the
fact that they are not exactly similar to those in other tissues57,58
has led to the development of specific adrenergic agonists. Yen er
al. 86•87 have recently used a {3-receptor agonist (LY 79771) to
reduce body weight and increase metabolic rate, thermogenesis
and lipolysis in obese mice. The drug did not inhibit appetite.
Arch er al. 88 and Arch and Ainsworth89 have used a {3-adrenergic
agonist (BRL 26830A) which is specific for BAT of rats. It has
been shown to stimulate thermogenesis and reduce body weight in
genetic, gold thioglucose- and cafeteria-fed obese rats. The drug
had no effect on their lean counterparts.
Recent studies by Triscari and Sullivan90 in rats have focused
on a novel inhibitor of hepatic fany acid synthesis (R022-0654).
Weight gain was decreased in lean and obese rats and could be
accounted for by a decrease in total body· lipid. Appetite was only
transiently affected.
Knoll9' of Budapest has described a naturally occurring glyco-
protein (satietin) which is non-addictive, does not affect body
temperature and has anorexic properties.
A further angle of approach is through·the in virro culture work
with pre-adipocytes which is being done in many laboratories. 24,92
The results may shed some light on the process of adipocyte
proliferation. Some preliminary work suggests that a serum-derived
factor may initiate the process.93 This has obvious therapeutic
potential.
Hyperinsulinaemia is frequently present in obesity, and in some
cases may contribute to the condition. Anempts are being made94,95
to synthesize somatostatin analogues (e.g WY-18166, Wyeth
Laboratories) which specifically inhibit insulin release and do not
affect release of growth hormone or glucagon. Some preliminary
work has also been done by Yen er al. 96 (Eli Lilly Research
Laboratories) using dehydroepiandrosterone, which inhibits
glucose-6-phosphate dehydrogenase activity (rate-limiting enzyme
in hexose monophosphate shunt pathway), and it has been shown
to reduce body fat in growing obese mice.
Conclusion
It is now realized that obesity is enormously more complex
than was previously thought. Homeostatic body weight
mechanisms make it difficult to treat, although recent research
gives some hope for therapeutic intervention in the near
future. The study of obesity and adipocytes is continuing to
shed light on physiological, hormonal and metabolic
mechanisms which may have application not only to adipocytes
and obesity, but to many other ceIl types and to many
diseases. These studies are concerned with such basic problems
as the control of cellular proliferation, the tissue-specific utili-
zation of substrates, alterations in blood flow to and oxygen
status of specific tissues in vivo, and alterations at the second
messenger level which will ultimately control cellular behaviour
and intracellular metabolic fate. The unravelling of the
molecular pathology of obesity will undoubtedly give answers
with far-reaching consequences.
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Neurobehavioural effects in rats
fed low doses of cadmium and lead to
induce hypertension
C. J. LOCKETT, W. P. LEARY
The neurochemical explanation for
Summary neurobehavioural effects
Rats given diets supplemented with low doses of
cadmium or lead or both elements together showed
an increase in cadmium levels within the brain in all
supplemented groups. Hypo-activity was noted after
16 months of dietary supplementation with lead or
with cadmium and lead. Activity was unaffected by
feeding with cadmium alone.
S Atr Med J t 986; 69: 190-192-
Reports on the neurophysiological and behavioural effects of
lead, both in animals and in humans, are numerous and
complex. Investigators who have measured activity in rats
given lead in accordance with various protocols and at different
stages of development have found that it can promote hyper-
activity or hypo-activity, or even produce no apparent change
in activity. Most of the literature makes it clear that the
developing brain is at greatest risk, possibly because the
permeability of the immature blood/brain barrier to lead is
greater than that in adult or post-weanling rats.
It has also been established 1-11 that lead and cadmium
ingested in small amounts may cause hypertension in experi-
mental animals. Since hypertension can be induced by stress
in an animal model,12 and hyperactivity and aggression are
established symptoms of lead toxicity,l3 the question arises
whether hyperactivity or other changes in neurobehavioural
panerns correlate with the hypertension produced by the
ingestion of trace metals.
Department of Experimental and Clinical Pharmacology,
University of Natal, Durban
C. }. LOCKETT, M.SC.
w. P. LEARY, M.SC., M.B. B.CH., D.PHIL., F.C.P. (SA), F.R.C.P.
At low doses lead inhibits the following enzymes in the brain:
tetrahydrobiopterin synthetase, dihydrobiopterin reductase,
adenyl cyclase, aminolaevulinic acid (ALA)-dehydrase, (Na+
+ K+)-adenosine triphosphatase (ATPase), K-nucleophospha-
tase (NPPase), gamma-aminobutyric acid (GABA)-transami-
nase, glutaminase, aldolase, acetylcholinesterase and butyryl-
cholinesterase. The biopterins are enzyme co-factors involved
in the biosynthesis of the neurotransminers dopamine and
noradrenaline. 13 Some of the effects of lead on GABA meta-
bolism may result from the ability of ALA, levels of which are
characteristically elevated by exposure to lead, to act as a 'false
neurotransminer' mimicking the structurally related GABA.
However, a recent study indicates that lead does not alter pre-
synaptic actions of brain choline or GABA when calcium
levels are normal. I4 In summary, the effects of lead appear to
be impairment of inhibitory neurochemical functions and sensi-
tization to stress. In the laner effect, the overall inhibition of
GABA may play an important role.
Effects of cadmium on the
central nervous system
The administration of cadmium results in decreased activity of
the Na,K,Mg2-dependent ATPase of brain, both in vitro and
in vivo. In increasing doses cadmium abolishes reflexes, then
the sensation of pain, and finally causes death by asphyxia due
to pulmonary oedema. It has been suggested that the marked
prostration, flaccidity of muscles and respiratory paralysis
observed in rats after intravenous injections of toxic doses of
cadmium may be due to displacement of calcium ions from
their action sites. 13
Aims
The objective of the present experiment was to examine the
relationship between brain trace element levels and neuro-
behavioural activiry, using an animal activity monitor, in
